Thromboxane A Synthase: A New Target for the Treatment of Cardiovascular Diseases

Author(s): Dinara F. Mesitskaya, Abram L. Syrkin, Marina G. Aksenova, Yong Zhang, Andrey A. Zamyatnin Jr.*, Philipp Y. Kopylov*

Journal Name: Cardiovascular & Hematological Agents in Medicinal Chemistry
Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents

Volume 16 , Issue 2 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Atherothrombosis-related diseases are one of the world’s leading causes of mortality, and thus the search for new therapeutic approaches in this area remains a very urgent task. Modern pharmacogenomic technologies make it possible to obtain valuable data on disease pathogenesis and optimal therapeutic approaches. One promising research direction is the study of the thromboxane A2 - thromboxane A synthase - thromboxane A2 receptor axis. This review summarizes the recent evidence and suggests that systematic works in this area are creating new and promising opportunities in the treatment of patients with cardiovascular diseases.

Keywords: Inhibitors of thromboxane A2-synthase, pharmacogenetics, thromboxane A synthase, thromboxane, cardiovascular diseases, prostaglandins.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 23 January, 2019
Page: [81 - 87]
Pages: 7
DOI: 10.2174/1871525716666180724115132
Price: $65

Article Metrics

PDF: 134
PRC: 1